Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opaganib in Refractory/Relapsed Multiple Myeloma
NCT02757326Phase 2Terminated
- Sponsor
- RedHill Biopharma
- Start
- Dec 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Opaganib in multiple myeloma (MM), sponsored by RedHill Biopharma. Started Dec 2016; status: terminated.
02
Drugs
Opaganib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02757326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757326.